Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Clene Inc. CLNN
$0.88
-$0.01 (-1.12%)
На 18:04, 12 мая 2023
+1 036.36%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
71295216.00000000
-
week52high
5.13
-
week52low
0.87
-
Revenue
473000
-
P/E TTM
-4
-
Beta
0.36715400
-
EPS
-0.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 11:49
Описание компании
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 18 июл 2022 г. | |
| Canaccord Genuity | Buy | 02 мая 2022 г. | |
| Maxim Group | Buy | 20 мая 2021 г. | |
| Cantor Fitzgerald | Overweight | 03 мая 2021 г. | |
| Benchmark | Buy | 02 мар 2021 г. | |
| Oppenheimer | Perform | Outperform | 04 окт 2022 г. |
| Canaccord Genuity | Buy | Buy | 04 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stevens John Henry | A | 9373 | 9373 | 02 февр 2023 г. |
| Mosca Alison | A | 12430 | 12430 | 02 февр 2023 г. |
| Gay Jonathon | A | 8966 | 8966 | 02 февр 2023 г. |
| Ugwumba Chidozie | A | 9679 | 9679 | 02 февр 2023 г. |
| MATLIN DAVID J | A | 15894 | 15894 | 02 февр 2023 г. |
| McLaughlin Vallerie | A | 8966 | 8966 | 02 февр 2023 г. |
| Jacobovitz Shalom | A | 12124 | 12124 | 02 февр 2023 г. |
| WILCOX REED N | A | 0 | 174912 | 14 ноя 2022 г. |
| WILCOX REED N | A | 575145 | 174912 | 14 ноя 2022 г. |
| Mortenson Mark | A | 400000 | 400000 | 04 ноя 2022 г. |
Новостная лента
Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
07 ноя 2022 г. в 11:32
Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
PennyStocks
30 сент 2022 г. в 18:32
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
GlobeNewsWire
30 сент 2022 г. в 16:12
Conference Call and Webcast Set for 8:30 a.m. EDT Conference Call and Webcast Set for 8:30 a.m. EDT
Clene to Present at Upcoming September Investor Conferences
GlobeNewsWire
30 авг 2022 г. в 07:00
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences in September:
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
15 авг 2022 г. в 09:47
Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?